Switching from concomitant therapy to tafluprost/timolol fixed combination

Kenji Inoue, Taku Kawashima, Seiki Katakura, Kyoko Shidara, Takayuki Fujimoto, Hiromi Kohmoto, Minako Shiokawa, Ryo Moriyama, Ryoko Okayama Inouye Eye Hospital, Tokyo, Japan Purpose: To evaluate the efficacy and safety of tafluprost/timolol fixed combination (TTFC). Study design: A prospective cli...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Inoue K, Kawashima T, Katakura S, Shidara K, Fujimoto T, Kohmoto H, Shiokawa M, Moriyama R, Okayama R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Tafluprost/timolol fixed combination switching intraocular pressure adverse reactions Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/a6552ab3288543888341d272a9db6b9b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a6552ab3288543888341d272a9db6b9b
record_format	dspace
spelling	oai:doaj.org-article:a6552ab3288543888341d272a9db6b9b2021-12-02T02:40:26ZSwitching from concomitant therapy to tafluprost/timolol fixed combination1177-5483https://doaj.org/article/a6552ab3288543888341d272a9db6b9b2018-03-01T00:00:00Zhttps://www.dovepress.com/switching-from-concomitant-therapy-to-tafluprosttimolol-fixed-combinat-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Kenji Inoue, Taku Kawashima, Seiki Katakura, Kyoko Shidara, Takayuki Fujimoto, Hiromi Kohmoto, Minako Shiokawa, Ryo Moriyama, Ryoko Okayama Inouye Eye Hospital, Tokyo, Japan Purpose: To evaluate the efficacy and safety of tafluprost/timolol fixed combination (TTFC). Study design: A prospective clinical study. Methods: Twenty-eight patients (28 eyes) with primary open-angle glaucoma, who had used tafluprost and timolol gel for at least 3 months with good adherence, were enrolled. Concomitant administration of tafluprost and timolol was switched to TTFC without a washout period. The intraocular pressure (IOP), blood pressure, pulse rate, and ocular signs were compared between before switching (baseline), and 4 and 8 weeks after switching. A questionnaire survey was also performed 4 weeks after switching to investigate ocular comfort and patient preferences. Results: The IOP showed no significant change after switching to TTFC (14.8 ± 2.8, 14.6 ± 3.4, and 14.8 ± 3.7 mmHg at baseline, Week 4, and Week 8, respectively). The pulse rate and systolic blood pressure showed no changes, but diastolic blood pressure was significantly lower at Week 8. At baseline, fluorescein staining revealed corneal abnormalities in 3 patients, which resolved by Week 8 in 1 patient. Hyperemia was noted in 2 patients at baseline, and this also resolved by Week 8 in 1 patient. Three patients discontinued study treatment for the following reasons (1 patient each): blurred vision; ocular irritation, eyelid erythema, and asthenopia; and loss to follow-up from Week 8. The questionnaire survey revealed no significant differences between the 2 treatments, although more patients preferred TTFC. Conclusion: Among 28 patients enrolled, only 2 patients discontinued the study treatment due to adverse reactions. In patients whose adherence was considered relatively good to concomitant therapy, switching to TTFC achieved similar IOP control with good safety and a high level of patient acceptance. Keywords: tafluprost/timolol fixed combination, switching, intraocular pressure, adverse reactionsInoue KKawashima TKatakura SShidara KFujimoto TKohmoto HShiokawa MMoriyama ROkayama RDove Medical PressarticleTafluprost/timolol fixed combinationswitchingintraocular pressureadverse reactionsOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 549-554 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Tafluprost/timolol fixed combination switching intraocular pressure adverse reactions Ophthalmology RE1-994
spellingShingle	Tafluprost/timolol fixed combination switching intraocular pressure adverse reactions Ophthalmology RE1-994 Inoue K Kawashima T Katakura S Shidara K Fujimoto T Kohmoto H Shiokawa M Moriyama R Okayama R Switching from concomitant therapy to tafluprost/timolol fixed combination
description	Kenji Inoue, Taku Kawashima, Seiki Katakura, Kyoko Shidara, Takayuki Fujimoto, Hiromi Kohmoto, Minako Shiokawa, Ryo Moriyama, Ryoko Okayama Inouye Eye Hospital, Tokyo, Japan Purpose: To evaluate the efficacy and safety of tafluprost/timolol fixed combination (TTFC). Study design: A prospective clinical study. Methods: Twenty-eight patients (28 eyes) with primary open-angle glaucoma, who had used tafluprost and timolol gel for at least 3 months with good adherence, were enrolled. Concomitant administration of tafluprost and timolol was switched to TTFC without a washout period. The intraocular pressure (IOP), blood pressure, pulse rate, and ocular signs were compared between before switching (baseline), and 4 and 8 weeks after switching. A questionnaire survey was also performed 4 weeks after switching to investigate ocular comfort and patient preferences. Results: The IOP showed no significant change after switching to TTFC (14.8 ± 2.8, 14.6 ± 3.4, and 14.8 ± 3.7 mmHg at baseline, Week 4, and Week 8, respectively). The pulse rate and systolic blood pressure showed no changes, but diastolic blood pressure was significantly lower at Week 8. At baseline, fluorescein staining revealed corneal abnormalities in 3 patients, which resolved by Week 8 in 1 patient. Hyperemia was noted in 2 patients at baseline, and this also resolved by Week 8 in 1 patient. Three patients discontinued study treatment for the following reasons (1 patient each): blurred vision; ocular irritation, eyelid erythema, and asthenopia; and loss to follow-up from Week 8. The questionnaire survey revealed no significant differences between the 2 treatments, although more patients preferred TTFC. Conclusion: Among 28 patients enrolled, only 2 patients discontinued the study treatment due to adverse reactions. In patients whose adherence was considered relatively good to concomitant therapy, switching to TTFC achieved similar IOP control with good safety and a high level of patient acceptance. Keywords: tafluprost/timolol fixed combination, switching, intraocular pressure, adverse reactions
format	article
author	Inoue K Kawashima T Katakura S Shidara K Fujimoto T Kohmoto H Shiokawa M Moriyama R Okayama R
author_facet	Inoue K Kawashima T Katakura S Shidara K Fujimoto T Kohmoto H Shiokawa M Moriyama R Okayama R
author_sort	Inoue K
title	Switching from concomitant therapy to tafluprost/timolol fixed combination
title_short	Switching from concomitant therapy to tafluprost/timolol fixed combination
title_full	Switching from concomitant therapy to tafluprost/timolol fixed combination
title_fullStr	Switching from concomitant therapy to tafluprost/timolol fixed combination
title_full_unstemmed	Switching from concomitant therapy to tafluprost/timolol fixed combination
title_sort	switching from concomitant therapy to tafluprost/timolol fixed combination
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/a6552ab3288543888341d272a9db6b9b
work_keys_str_mv	AT inouek switchingfromconcomitanttherapytotafluprosttimololfixedcombination AT kawashimat switchingfromconcomitanttherapytotafluprosttimololfixedcombination AT katakuras switchingfromconcomitanttherapytotafluprosttimololfixedcombination AT shidarak switchingfromconcomitanttherapytotafluprosttimololfixedcombination AT fujimotot switchingfromconcomitanttherapytotafluprosttimololfixedcombination AT kohmotoh switchingfromconcomitanttherapytotafluprosttimololfixedcombination AT shiokawam switchingfromconcomitanttherapytotafluprosttimololfixedcombination AT moriyamar switchingfromconcomitanttherapytotafluprosttimololfixedcombination AT okayamar switchingfromconcomitanttherapytotafluprosttimololfixedcombination
_version_	1718402310019743744

Switching from concomitant therapy to tafluprost/timolol fixed combination

Ejemplares similares